Siliq

Active Ingredient(s): Brodalumab
FDA Approved: * February 15, 2017
Pharm Company: * VALEANT LUXEMBOURG
Category: Immune System

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Siliq Overview

Brodalumab (trade name Siliq) is a human monoclonal antibody designed for the treatment of inflammatory diseases.[1] In February 2017 it received US FDA approval to treat moderate to severe psoriasis in people who have not improved with other treatments.[2] Use is linked to an increased risk of suicide.[2] Mechanism of action Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. (This mechanism is similar to that of another anti...

Read more Siliq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brodalumab

Recent Siliq Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Brodalumab
  • Injection: 210mg/1.5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Siliq: (1 result)

Sorted by National Drug Code
  • 0187-0004 Siliq 210 mg Subcutaneous Injection by Valeant Pharmaceuticals North America LLC

Other drugs which contain Brodalumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 27 May 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.